NCT05272826 2026-03-18
BOREALIS
Canadian Myeloma Research Group
Phase 2 Recruiting
Clinical Trials
23 trialsNCT05690984 2026-03-16
EMAT
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT04883242 2026-03-13
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
University of Washington
Phase 2 Active not recruiting
NCT06832865 2026-03-12
ELISA in Relapsed/Refractory MM
Massachusetts General Hospital
Phase 2 Recruiting
NCT05873205 2026-03-02
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05344833 2026-02-23
HEME-18
University of Illinois at Chicago
Phase 2 Recruiting
NCT04430894 2026-01-29
KRDI in Transplant-Eligible MM
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04240054 2026-01-28
VICD
Medical College of Wisconsin
Phase 2 Recruiting
NCT06648889 2026-01-15
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
Goethe University
Phase 2 Recruiting
NCT05922501 2026-01-14
ISABELA
Massachusetts General Hospital
Phase 2 Recruiting
NCT05704049 2025-12-29
IZALCO
Sanofi
Phase 2 Active not recruiting
NCT04653246 2025-12-23
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04850599 2025-12-18
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT06517017 2025-11-28
UltraFrailMM
University of Utah
Phase 2 Recruiting
NCT04126200 2025-11-06
DREAMM5
GlaxoSmithKline
Phase 2 Active not recruiting
NCT05911321 2025-10-20
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05145400 2025-09-26
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT03499808 2025-09-09
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
SWOG Cancer Research Network
Phase 2 Completed
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT06762769 2025-08-01
MODIFY
University College, London
Phase 2 Recruiting
NCT05123131 2025-07-08
Isa-RVD
Cancer Trials Ireland
Phase 2 Active not recruiting
NCT05346809 2025-06-08
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
Columbia University
Phase 2 Recruiting
NCT04891809 2025-04-10
Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Active not recruiting